Skip to main content

Table 3 Results from extended complement analyses, Skåne laboratory, Lund University, Sweden

From: The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report

Lab Results (Skåne)

Unit [ref] \ Day #

1

36

CD46/MCP

 

5,1 MFI

 

Alternative pathway function

% [30-113]

16

<1

Complement C3

g/L [0.77-1.38]

0.48

 

Complement C3d

mg/L [< 5]

19.1

 

Factor B concentration

% [59-154]

103

 

Factor H concentration

% [69-154]

25

137

Anti-factor H antibodies

U/ml [< 99]

< 99

<99

Factor I concentration

% [60-152]

74

 
  1. Genetic analyses, day 90: Heterozygous variant factor B Gly252Ser (population frequency 2%)